Log in to save to my catalogue

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_csuc_recercat_oai_recercat_cat_2072_354400

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year recurrence-free survival rate of 75%, as compared with 61% for placebo.

Alternative Titles

Full title

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_csuc_recercat_oai_recercat_cat_2072_354400

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_csuc_recercat_oai_recercat_cat_2072_354400

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1802357

How to access this item